{"nctId":"NCT01347073","briefTitle":"Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs)","startDateStruct":{"date":"2011-07"},"conditions":["Urea Cycle Disorders"],"count":23,"armGroups":[{"label":"HPN-100","type":"EXPERIMENTAL","interventionNames":["Drug: HPN-100"]}],"interventions":[{"name":"HPN-100","otherNames":["RAVICTI","Glycerol phenylbuterate"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female subjects 29 days to \\< 6 years old. If the subject is born prematurely, calculation of the lower age limit begins at the corrected gestational age of 40 weeks.\n* Signed informed consent by the subject's legally acceptable representative\n* Suspected or confirmed UCD diagnosis of any subtype, except NAGS deficiency\n* On stable dose of NaPBA powder for at least 5 days before Day 1\n* Not receiving sodium benzoate for at least 5 days before Day 1\n* No concomitant illness which would preclude safe participation as judged by the investigator\n* Able to receive medication orally\n* Has not undergone liver transplantation, including hepatocellular transplantation\n* Judged sufficiently stable and compliant with diet and treatment to be suitable for enrollment\n\nExclusion Criteria:\n\n* Screening ammonia level \\> 100 μmol/L and signs and symptoms indicative of hyperammonemia; subjects may be rescreened after their ammonia is controlled and they are clinically stable, at the discretion of the investigator\n* Use of any investigational drug within 30 days of Day 1\n* Active infection (viral or bacterial) or any other condition that may increase ammonia levels\n* Any clinical or laboratory abnormality of Grade 3 or greater severity according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.03, except Grade 3 elevations in ammonia and liver enzymes, defined as levels 5-20 times ULN (upper limit of normal)in alanine aminotransferase (ALT), aspartate aminotransferase (AST), or gamma glutamyl transpeptidase (GGT) in a clinically stable subject\n* Any clinical or laboratory abnormality or medical condition that, at the discretion of the investigator, may put the subject at increased risk by participating in this study\n* Known hypersensitivity to PAA or PBA\n* Liver transplant, including hepatocellular transplant\n* Currently treated with Carbaglu® (carglumic acid)","healthyVolunteers":false,"sex":"ALL","minimumAge":"29 Days","maximumAge":"6 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Adverse Events","description":"Rate of adverse events during the Switch-Over portion of the Protocol","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Blood Ammonia","description":"24-hour ammonia AUC of blood ammonia levels on Days 1 (NaPBA) and 10 (HPN-100) were compared. Ammonia was assessed at Hour 0 (pre-first dose, fasted), Hour 8 (\\~2-4 hours after lunch or the second main meal and dose of NaPBA), Hour 12 (\\~4 hours after the last main meal) and 24 hours post-first dose (pre-first dose on following day, fasted).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"914.43","spread":"630.21"},{"groupId":"OG001","value":"647.63","spread":"379.94"}]}]}]},{"type":"SECONDARY","title":"Frequency of Ammonia Levels Greater Than the Upper Limit of Normal (ULN) on HPN-100 Compared With NaPBA","description":"Ammonia values were converted to SI units (umol/L) and normalized to a standard ULN of 35 umol/L prior to analysis","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Hyperammonemic Crisis","description":"Rate of HAC during pre-enrollment on NaPBA compared to HAC during HPN-100 treatment","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"PRIMARY","title":"Adverse Events","description":"Rate of adverse events during the Safety Extension portion of the protocol ( please note: HPN-100 treatment only during Safety Extension )","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":23},"commonTop":["Upper respiratory tract infection","Vomiting","Pyrexia","Hyperammonemia","Diarrhea"]}}}